Anidulafungin Vicuron.

Abstract

Anidulafungin, a 1,3-beta-glucan synthesis inhibitor and the pentyloxyterphenyl side chain derivative of echinocandin B, is being developed by Vicuron Pharmaceuticals Inc, under license from Eli Lilly & Co, for the potential treatment of fungal infection.

• Authors: Estrella Martin-Mazuelos
• Journal: IDrugs : the investigational drugs journal (IDrugs) Vol. 6 Issue 10 Pg. 980-6 (Oct 2003) ISSN: 1369-7056 [Print] England
• PMID: 14534856 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents
• Drugs, Investigational
• Echinocandins
• Peptides, Cyclic
• Anidulafungin

Topics

• Anidulafungin
• Animals
• Antifungal Agents (chemistry, pharmacology, therapeutic use)
• Clinical Trials as Topic (statistics & numerical data)
• Drugs, Investigational (chemistry, pharmacology, therapeutic use)
• Echinocandins
• Humans
• Peptides, Cyclic (chemistry, pharmacology, therapeutic use)